Core Insights - The company achieved total product revenue exceeding RMB 3.3 billion in Q3 2025, reflecting a robust year-on-year growth of approximately 40% driven by both oncology and comprehensive product lines [1] Oncology Sector - The company maintains a leading position in the oncology treatment field, with significant advantages in its product portfolio, including steady growth of key products like Dabu Shu (sintilimab injection) [1] - The contribution of innovative product revenue has further increased, enhancing the overall revenue mix [1] Comprehensive Product Line - The potential of the comprehensive product line is rapidly being realized, providing new growth drivers with significant revenue contributions from products like Xin Er Mei (masitinib injection), Xin Bi Le (toripalimab injection), and Xin Bi Min (tremelimumab N01 injection) [1] - Successful market access and channel marketing efforts have accelerated product uptake, leading to substantial revenue growth [1] - The second indication for masitinib for diabetes has also received approval from the National Medical Products Administration of China, expanding access to high-quality innovative treatment options for a broader patient base [1] Strategic Focus - The company is committed to sustainable growth and global innovation as its two core strategies, with a rich pipeline in oncology and comprehensive product lines (cardiovascular, metabolism, autoimmune, ophthalmology) [1] - As of now, the company has obtained approvals for 16 products, with 2 under review by the National Medical Products Administration of China, and 4 new drug molecules in Phase 3 or pivotal clinical studies, alongside approximately 15 new drug candidates in clinical research [1] - The year 2025 marks a significant milestone for the company as it enters a new phase of dual-driven growth and global innovation, progressing towards its vision of becoming a world-class biopharmaceutical company [1]

Core Insights - The company reported total product revenue exceeding RMB 5.2 billion for the first half of the year, maintaining a strong growth rate of over 35% year-on-year [1] - In Q2 2025, total product revenue surpassed RMB 2.7 billion, with a year-on-year growth of over 30%, driven by both oncology and comprehensive pipelines [1] Oncology and Comprehensive Pipeline - The oncology treatment sector continues to show strong performance with leading brands and product combinations, while new product revenue contributions are steadily increasing [1] - The comprehensive product line is gradually releasing its potential, with new drivers of growth coming from products like Xinbile® (Tolebrutinib injection) and Xinbimin® (Tremelimumab N01 injection), which are making progress in marketing and channel access [1] - The approval of the world's first glucagon/GLP-1 dual receptor agonist, Xinermai® (Masitide injection), for weight loss indications by the National Medical Products Administration of China adds a significant product to the company's comprehensive pipeline [1] Product Approvals and Clinical Research - The company has successfully obtained approvals for 16 products, with 2 additional products under review by the National Medical Products Administration of China [1] - Four new drug molecules are currently in Phase 3 or pivotal clinical studies, and approximately 15 new drug candidates have entered clinical research [1]

Group 1 - The company reported total product revenue exceeding RMB 5.2 billion in the first half of 2025, maintaining a strong growth of over 35% year-on-year [1] - In Q2 2025, total product revenue surpassed RMB 2.7 billion, with a year-on-year growth of over 30%, driven by both oncology and comprehensive product lines [1] - The growth in the oncology treatment sector is attributed to a strong brand and product portfolio, with major products showing excellent growth and new product contributions increasing [1] Group 2 - The company is focused on sustainable growth and global innovation, with a rich pipeline in oncology and comprehensive product lines (cardiovascular and metabolic, autoimmune, and ophthalmology) [2] - As of now, the company has obtained approval for 16 products, with 2 under review by the National Medical Products Administration of China, and 4 new drug molecules in Phase 3 or pivotal clinical studies [2] - The year 2025 marks an important period for the company as it aims to become an internationally leading biopharmaceutical company [2]